FTIDC

FTIDC is an orally active, noncompetitive, selective allosteric metabotropic glutamate receptor (mGluR) 1 antagonist with an IC50 of 5.8 nM for human mGluR1a. FTIDC has no species differences in its antagonistic activity on recombinant human, mouse, and rat mGluR1[1].

Product Specifications

CAS Number

[873551-53-2]

UNSPSC

12352005

Target

MGluR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ftidc.html

Concentration

10mM

Purity

99.34

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(N1CC=C(C2=C(C)N(C3=CC=CN=C3F)N=N2)CC1)N(C)C(C)C

Molecular Formula

C18H23FN6O

Molecular Weight

358.41

References & Citations

[1]Suzuki G, et al. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1- (2-fluoropyridin-3-yl) -5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1 (2H) -carboxamide (FTIDC) . J Pharmacol Exp Ther. 2007 Jun;321 (3) :1144-53.